Other languages KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Real-time Estimate Cboe BZX Other stock markets 03:58:28 2024-05-21 pm EDT			5-day change	1st Jan Change
11.62 ^USD	-2.19%		-8.01%	-6.20%

Apr. 22	Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	CI
Apr. 15	Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	Apr. 22
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas	Mar. 18
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	Mar. 11
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas	Mar. 08
KalVista Pharmaceuticals Names Benjamin Palleiko as CEO	Mar. 07
KalVista Pharmaceuticals, Inc. Announces Board Changes	Mar. 07
KalVista Pharmaceuticals, Inc. Announces Chief Executive Officer Changes	Mar. 07
Kalvista Pharmaceuticals Insider Sold Shares Worth $613,205, According to a Recent SEC Filing	Feb. 16
Kalvista Pharmaceuticals Insider Sold Shares Worth $598,661, According to a Recent SEC Filing	Feb. 16
Kalvista Pharmaceuticals Insider Sold Shares Worth $422,827, According to a Recent SEC Filing	Feb. 16
KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting	Feb. 16
KalVista Pharmaceuticals' Phase 3 Trial of Sebetralstat to Treat Hereditary Angioedema Meets All Endpoints; Shares Rise	Feb. 13
KalVista meets main goals in late-stage trial for genetic disease	Feb. 13
KalVista meets main goals in late-stage trial for skin condition treatment	Feb. 13
Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema	Feb. 13
Kalvista Pharmaceuticals Insider Sold Shares Worth $295,514, According to a Recent SEC Filing	Jan. 12
Kalvista Pharmaceuticals Insider Sold Shares Worth $360,453, According to a Recent SEC Filing	Dec. 28
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	Dec. 07
KalVista Pharmaceuticals' Clinical Trial Reaches Milestone Needed to Complete Drug Candidate's Study	Nov. 13
Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved	Nov. 13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Other languages

Filters